Jane Street Group LLC Makes New $74,000 Investment in Coya Therapeutics, Inc. (NASDAQ:COYA)

Jane Street Group LLC bought a new stake in Coya Therapeutics, Inc. (NASDAQ:COYA) during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund bought 12,961 shares of the company’s stock, valued at approximately $74,000. Jane Street Group LLC owned 0.08% of Coya Therapeutics at the end of the most recent quarter.

Other large investors have also modified their holdings of the company. Tower Research Capital LLC TRC grew its position in Coya Therapeutics by 1,005.7% in the 4th quarter. Tower Research Capital LLC TRC now owns 5,252 shares of the company’s stock valued at $30,000 after buying an additional 4,777 shares during the last quarter. XTX Topco Ltd acquired a new stake in shares of Coya Therapeutics in the 4th quarter worth $59,000. Northern Trust Corp boosted its holdings in shares of Coya Therapeutics by 12.2% in the fourth quarter. Northern Trust Corp now owns 28,549 shares of the company’s stock valued at $164,000 after acquiring an additional 3,099 shares in the last quarter. Newbridge Financial Services Group Inc. acquired a new position in shares of Coya Therapeutics during the fourth quarter worth about $401,000. Finally, Geode Capital Management LLC increased its stake in shares of Coya Therapeutics by 5.8% during the fourth quarter. Geode Capital Management LLC now owns 150,576 shares of the company’s stock worth $863,000 after acquiring an additional 8,267 shares during the period. Hedge funds and other institutional investors own 39.75% of the company’s stock.

Coya Therapeutics Trading Up 1.9%

COYA stock opened at $5.88 on Monday. The company’s 50-day moving average price is $5.79 and its 200 day moving average price is $6.05. Coya Therapeutics, Inc. has a 52 week low of $4.65 and a 52 week high of $10.24. The company has a market cap of $98.34 million, a P/E ratio of -9.05 and a beta of 0.21.

Coya Therapeutics (NASDAQ:COYA) last announced its quarterly earnings results on Tuesday, May 13th. The company reported ($0.44) EPS for the quarter, hitting the consensus estimate of ($0.44). The firm had revenue of $257.88 million for the quarter, compared to analysts’ expectations of $2.63 million. On average, equities research analysts expect that Coya Therapeutics, Inc. will post -1.15 earnings per share for the current year.

Analysts Set New Price Targets

COYA has been the topic of a number of analyst reports. Chardan Capital reaffirmed a “buy” rating and issued a $14.00 price objective on shares of Coya Therapeutics in a report on Tuesday, May 13th. Wall Street Zen cut Coya Therapeutics from a “hold” rating to a “sell” rating in a report on Thursday, May 22nd. Finally, D. Boral Capital reaffirmed a “buy” rating and set a $18.00 price objective on shares of Coya Therapeutics in a report on Tuesday, April 22nd. One investment analyst has rated the stock with a sell rating and four have issued a buy rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $17.00.

Coya Therapeutics Profile

Coya Therapeutics, Inc, a clinical-stage biotechnology company, engages in the development of proprietary medicinal products to modulate the function of regulatory T cells (Tregs). The company's product candidate pipeline is based on therapeutic modalities, such as Treg-enhancing biologics, Treg-derived exosomes, and autologous Treg cell therapy.